(2) Cav‐1 agonists: Enhancing Cav‐1 function may be beneficial in some cases, such as in SSc, where Cav‐1 activation promotes angiogenesis and inhibits fibrosis, potentially slowing the progression of the disease. The gene discussed is CAV1; the disease is systemic sclerosis.